Engineered iPSC ‐derived natural killer cells: recent innovations in translational innate anti‐cancer immunotherapy
Clinical & Translational Immunology · 2025-01 · 14 (7)
DOI: 10.1002/cti2.70045 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical & Translational Immunology, online erschienen am 10.07.2025. Verfasst von Jane Sun und 2 weiteren Autor:innen. Beteiligte Einrichtung: Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences The University of Queensland Brisbane QLD Australia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Metro South Health.
Abstract (Originalsprache)
Natural killer (NK) cells are increasingly recognised as potent tumoricidal agents that can be utilised for cancer immunotherapy. Their innate cytotoxicity against tumor cells, and reduced risk of causing transplantation or toxicity issues in patients, makes them a valuable option for exploration in allogeneic adoptive cell immunotherapies. However, sourcing NK cells from peripheral blood poses challenges in terms of scalability, consistency and variability. Induced pluripotent stem cells (iPSCs) are emerging as a platform to create specific cells with highly controlled processes, allowing for a common cell source for cell therapies and offering a promising inexhaustible source of genetically modifiable NK cells. This review highlights recent developments in the field of generating iPSC‐derived NK cells in defined culture systems, and advancements in genetic modification to improve iPSC‐NK cell therapy. We further discuss the development of iPSC banks and examine the potential of these cells in next‐generation immunotherapies. Finally, we summarise the improvements in cancer targeting, expansion, persistence and cytotoxic functionality of iPSC‐derived NK (iNK) cells both in vitro and in vivo , achieved through genetic modification of iPSCs, as well as recent related clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences The University of Queensland Brisbane QLD Australia.
ORCID-Profile: Fernando Souza-Fonseca-Guimaraes
Förderung
- Metro South Health
Zitieren
APA
Sun, J., Elliott, M., & Souza-Fonseca-Guimaraes, F. (2025). Engineered iPSC ‐derived natural killer cells: recent innovations in translational innate anti‐cancer immunotherapy. Clinical & Translational Immunology, 14(7). https://doi.org/10.1002/cti2.70045
Vancouver
Sun J, Elliott M, Souza-Fonseca-Guimaraes F. Engineered iPSC ‐derived natural killer cells: recent innovations in translational innate anti‐cancer immunotherapy. Clinical & Translational Immunology. 2025;14(7). doi:10.1002/cti2.70045
BibTeX
@article{Sun2025,
author = {Sun, Jane and Elliott, Melissa and Souza-Fonseca-Guimaraes, Fernando},
title = {Engineered iPSC ‐derived natural killer cells: recent innovations in translational innate anti‐cancer immunotherapy},
journal = {Clinical & Translational Immunology},
year = {2025},
volume = {14},
number = {7},
doi = {10.1002/cti2.70045}
}
EUVIMED